Compare Amphastar Pharmaceuticals Inc (AMPH) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Intuit Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Intuit Inc. trades at $336.22 (market cap $91.48B). The key difference: Intuit Inc. is far larger — about 105.9× Amphastar Pharmaceuticals Inc's market cap, and Intuit Inc. pays a 1.44% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | INTU | |
|---|---|---|
Market Cap | $863.95M | $91.48B |
Sector | Health | Technology |
52-Week High | $30.81 | $717.21 |
52-Week Low | $16.87 | $255.07 |
Enterprise Value | $1.26B | $89.94B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Intuit (INTU) trades at $336.44, up 3.44% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $18.83B in 2025, with a net income margin of 20.54%, while analyst consensus is a Buy with a $401 price target. However, recent news highlights a 20% stock drop and securities fraud investigations related to TurboTax pricing issues, creating near-term uncertainty.
The outlook is mixed: strong fundamentals and AI-driven growth in financial software support upside, but legal risks and investor sentiment pressure pose challenges. Valuation metrics like a P/E of 20.4 appear reasonable if execution continues, yet volatility may persist until legal concerns resolve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
